- Osteoarthritis therapeutics, including pharmacological agents, biologics, and intra-articular injections, are becoming increasingly vital components of musculoskeletal care in both primary and specialty healthcare settings due to their effectiveness in managing chronic joint pain, improving mobility, and delaying the need for surgical interventions
- The escalating demand for osteoarthritis therapeutics is primarily fueled by the aging global population, rising obesity rates, increasing awareness of joint health, and advancements in regenerative medicine and disease-modifying osteoarthritis drugs (DMOADs)
- North America dominated the osteoarthritis therapeutics market with the largest revenue share of 41.7% in 2024, driven by the high prevalence of osteoarthritis, strong healthcare infrastructure, favorable reimbursement policies, and the presence of major pharmaceutical companies investing in R&D for novel therapies. The U.S. continues to lead the region with widespread adoption of advanced treatment options such as platelet-rich plasma (PRP) injections and viscosupplementation
- Asia-Pacific is expected to be the fastest growing region in the osteoarthritis therapeutics market during the forecast period, with a CAGR of 9.6%, owing to rapidly aging populations, increasing healthcare spending, improving diagnosis rates, and a growing emphasis on non-surgical interventions across countries such as China, India, and Japan
- The viscosupplementation agents segment dominated the osteoarthritis therapeutics market with a market share of 34.5% in 2024, driven by their role in improving joint lubrication and delaying the need for surgical intervention. These agents are particularly effective in treating knee osteoarthritis and are widely adopted due to their minimal side effects
